TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials

SIMPLE SUMMARY: Sarcomas have a high recurrence rate and no validated genomic marker to guide decisions of peri-operative systemic treatments. We pooled two precision oncology trials in order to identify genomic markers prognostic and/or predictive of response to treatment with anthracyclines in sar...

Descripción completa

Detalles Bibliográficos
Autores principales: Nassif, Elise F., Auclin, Edouard, Bahleda, Rastilav, Honoré, Charles, Mir, Olivier, Dumont, Sarah, Mery, Benoite, Hodroj, Khalil, Brahmi, Mehdi, Trédan, Olivier, Ray-Coquard, Isabelle, Blay, Jean-Yves, Massard, Christophe, Le Cesne, Axel, Dufresne, Armelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268242/
https://www.ncbi.nlm.nih.gov/pubmed/34282771
http://dx.doi.org/10.3390/cancers13133362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268242/
https://www.ncbi.nlm.nih.gov/pubmed/34282771
http://dx.doi.org/10.3390/cancers13133362

Ejemplares similares